Literature DB >> 26596525

Quantification of the Mutant CALR Allelic Burden by Digital PCR: Application to Minimal Residual Disease Evaluation after Bone Marrow Transplantation.

Olivier Mansier1, Marina Migeon2, Arnaud Saint-Lézer3, Chloé James4, Emmanuelle Verger5, Marie Robin6, Gérard Socié6, Audrey Bidet2, François-Xavier Mahon1, Bruno Cassinat5, Eric Lippert7.   

Abstract

With the recent discovery of CALR mutations, >80% of patients with myeloproliferative neoplasms carry a phenotype-driving mutation. For JAK2 V617F, the most frequent mutation in myeloproliferative neoplasms, accurate determination of mutational loads is of interest at diagnosis, for phenotypic and prognostic purposes, and during follow-up for minimal residual disease assessment. We developed a digital PCR technique that allowed the accurate determination of CALR allelic burdens for the main mutations (types 1 and 2). Compared with the commonly used fluorescent PCR product analysis, digital PCR is more precise, reproducible, and accurate. Furthermore, this method reached a very high sensitivity. We detected at least 0.025% CALR mutants. It can thus be used for patient characterization at diagnosis and for minimal residual disease monitoring. When applied to patients with primary myelofibrosis who underwent hematopoietic stem cell transplant, the digital PCR detected low levels of minimal residual disease. After negativation of the mutational load in all patients, the disease reappeared at a low level in one patient, preceding hematologic relapse. In conclusion, digital PCR adapted to type 1 and 2 CALR mutations is an inexpensive, highly precise, and sensitive technique suitable for evaluation of myeloproliferative neoplasm patients during follow-up.
Copyright © 2016 American Society for Investigative Pathology and the Association for Molecular Pathology. Published by Elsevier Inc. All rights reserved.

Entities:  

Mesh:

Substances:

Year:  2015        PMID: 26596525     DOI: 10.1016/j.jmoldx.2015.07.007

Source DB:  PubMed          Journal:  J Mol Diagn        ISSN: 1525-1578            Impact factor:   5.568


  12 in total

1.  Absence of CALR mutations in JAK2-negative polycythemia.

Authors:  Aurélie Chauveau; Olivier Nibourel; Sylvie Tondeur; Damien Luque Paz; Olivier Mansier; Franciane Paul; Mathieu Wemeau; Claude Preudhomme; Eric Lippert; Valérie Ugo
Journal:  Haematologica       Date:  2016-10-06       Impact factor: 9.941

Review 2.  High-throughput sequencing for noninvasive disease detection in hematologic malignancies.

Authors:  Florian Scherer; David M Kurtz; Maximilian Diehn; Ash A Alizadeh
Journal:  Blood       Date:  2017-06-09       Impact factor: 22.113

3.  Differential Dynamics of CALR Mutant Allele Burden in Myeloproliferative Neoplasms during Interferon Alfa Treatment.

Authors:  Lasse Kjær; Sabrina Cordua; Morten O Holmström; Mads Thomassen; Torben A Kruse; Niels Pallisgaard; Thomas S Larsen; Karin de Stricker; Vibe Skov; Hans C Hasselbalch
Journal:  PLoS One       Date:  2016-10-20       Impact factor: 3.240

Review 4.  Monitoring Minimal Residual Disease in the Myeloproliferative Neoplasms: Current Applications and Emerging Approaches.

Authors:  Karl Haslam; Stephen E Langabeer
Journal:  Biomed Res Int       Date:  2016-10-20       Impact factor: 3.411

Review 5.  Digital PCR: A Reliable Tool for Analyzing and Monitoring Hematologic Malignancies.

Authors:  Nicoletta Coccaro; Giuseppina Tota; Luisa Anelli; Antonella Zagaria; Giorgina Specchia; Francesco Albano
Journal:  Int J Mol Sci       Date:  2020-04-29       Impact factor: 5.923

Review 6.  Digital PCR in Myeloid Malignancies: Ready to Replace Quantitative PCR?

Authors:  Daniela Cilloni; Jessica Petiti; Valentina Rosso; Giacomo Andreani; Matteo Dragani; Carmen Fava; Giuseppe Saglio
Journal:  Int J Mol Sci       Date:  2019-05-07       Impact factor: 5.923

Review 7.  The Genetic Basis of Primary Myelofibrosis and Its Clinical Relevance.

Authors:  Elisa Rumi; Chiara Trotti; Daniele Vanni; Ilaria Carola Casetti; Daniela Pietra; Emanuela Sant'Antonio
Journal:  Int J Mol Sci       Date:  2020-11-24       Impact factor: 5.923

8.  Digital PCR Panel for Sensitive Hematopoietic Chimerism Quantification after Allogeneic Stem Cell Transplantation.

Authors:  Tanja Stahl; Caroline Rothe; Manja U Böhme; Aloisa Kohl; Nicolaus Kröger; Boris Fehse
Journal:  Int J Mol Sci       Date:  2016-09-09       Impact factor: 5.923

Review 9.  Allogeneic hematopoietic stem-cell transplantation for myelofibrosis.

Authors:  Lining Zhang; Fan Yang; Sizhou Feng
Journal:  Ther Adv Hematol       Date:  2020-02-13

Review 10.  The Contemporary Approach to CALR-Positive Myeloproliferative Neoplasms.

Authors:  Tanja Belčič Mikič; Tadej Pajič; Samo Zver; Matjaž Sever
Journal:  Int J Mol Sci       Date:  2021-03-25       Impact factor: 5.923

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.